OFFICE PHONE: +46-736 00 10 98 michele.masucci@ki.se

The first National Workshop on PCM was held in Stockholm on the 6th of April 2016.

A meeting with prominent figures within the translational cancer research community in Sweden initiating a discussion that emphasizes innovations, their translations and validation of infrastructures for Precision Cancer Medicine.

The program from the meeting is found below.

National workshop on Personalized/Precision Cancer Medicine (PCM) 

Innovation and Validation of Infrastructures for PCM

Program

Date: April 6 2016, 9.00 – 17.45

Venue: Andreas Vesalius Auditorium, Berzelius väg 3, Karolinska Institutet, Solna

Wednesday 6th of April

Chair: Svetlana Bajalica-Lagercrantz and Ingemar Ernberg

9.00 – 9.10  Henrik Grönberg, Deputy President of KI.

Welcome note

9.10 – 9.20 Lars Hultman, SSF

Strategic Funding and Precision Medicine

9.20 – 9.30 Ingemar Ernberg, Dept of Microbiology, Tumor and Cell Biology (MTC), KI

Rolf Lewensohn, Dept of Oncology and Pathology, KI

                   The purpose of the meeting

9.30 – 9.45 Åke Borg, The Division of Oncology and Pathology at the Department of

Clinical Sciences, Lund

PCM in Lund

9.50 – 10.05 Tobias Sjöblom, Department of Immunology, Genetics and Pathology

Program Director for U-CAN, Uppsala

PCM and U-CAN: Biomarker discovery

10.10 -10.25 Claes Karlsson, Dept of Hematology, Karolinska University Hospital, Solna

The PCM initiative at KI

10.30 – 10.45 Coffee

10.45 – 11.00 Jonas Nilsson, Department of Surgery, Sahlgrenska Cancer Center at

University of Gothenburg

Melanoma patient-derived xenografts and cells for drug development &

                       precision medicine of metastatic malignant melanoma

11.05 Omics and Bioinformatics for PCM

Chair: Bertha Brodin and Tobias Sjöblom

11.05 -11.40 Olli Kallioniemi, SciLife and Dept of Oncology and Pathology, KI

           Setting up a clinical PCM program based on systems medicine: FIMM and

                    SciLifeLab

11.45 – 12.00 Johan Lindberg, Dept of Medical Epidemiology and Biostatitistics, KI

ClinSeq – an infrastructure for clinical sequencing of cancer

12.05 – 12.20 Lao Saal, The Division of Oncology and Pathology at the Department of

Clinical Sciences, Lund

Genomic sequencing of tumors and detection of circulating tumor DNA

12.25 – 13.30 Lunch

13.30 Molecular Pathology for PCM

13.30 – 13.45 Ulf Landegren, Department of  Immunology, Genetics and Pathology and

SciLifeLab, Uppsala University

                      Molecular tools for PCM

13.50 – 14.05 Johan Hartman, Dept of Oncology and Pathology, KI

Molecular Pathology for PCM

14.10 Clinical trials for PCM  

Chair: Åke Borg

14.10 -14.25 Jonas Bergh, Dept of Oncology and Pathology, KI

Breast Cancer

 

14.30 – 14.45 Göran Jönsson, The Division of Oncology and Pathology at the Department

of Clinical Sciences Lund

Malignant melanoma

 

14.50 – 15.05 Matthias Löhr, Department of Clinical Science, Intervention and

Technology (CLINTEC), KI

                      Pancreas cancer

15.10 -15.40 Coffee

15.40 – 15.55 Simon Ekman, Dept of Oncology and Pathology, KI

                      PCM for lung cancer, present and future

16.00 Cancer Immunotherapy as PCM

Chair: Sonia Lain and Rolf Lewensohn

16.00 – 16.35 David Lane, Dept of Microbiology, Tumor and Cell Biology (MTC), KI,

Singapore

Personalized cancer immunotherapy

16.40 – 17.05 Bengt Westermark, Department of Immunology, Genetics and Pathology,

Uppsala

                        The place of PCM in future Cancer Research

17.10 – 17.45 Panel discussion; a national task force for PCM?

17.45              Concluding remarks

Organising committee: Ingemar Ernberg, Olli Kallioniemi (SciLife), David Lane (KI), Åke Borg (Lund), Simon Ekman (KI), Johan Hartman (KI), Claes Karlsson (KI), Michele Masucci (KI), Rolf Lewensohn (KI)